ERBB2 and neoplasm: However, one of the most plausible reasons is that, although trastuzumab has a high anti-tumor effect against HER2-positive tumor cells, it is an antibody drug with a large molecular weight that makes it difficult to pass through the blood–brain barrier to control metastasis.